title: Description of current practices of empiric chemotherapy dose adjustment in obese adult patients.
abstract: OBJECTIVE
  The literature is not clear on the best method to empirically dose chemotherapy in obese adult patients. The purpose of our study was to determine whether a standard of practice existed, characterize current practices of empiric dose adjustment (EDA) in obese adult patients, and identify factors affecting this decision.
  
  
  METHODS
  An electronic survey was distributed to oncologists and board-certified oncology pharmacists via the Association of Community Cancer Centers and Board of Pharmaceutical Specialties e-mail distribution lists. The survey contained patient scenarios assessing the impact of various factors on EDA of chemotherapy, demographic information, and details of institutional policies.
  
  
  RESULTS
  Responses were collected from 174 professionals. Pharmacists comprised 95% of respondents. Of these, 50% practiced in academic medical centers, and 19% practiced in institutions with a standard of practice regarding EDA for obesity. The most common methods of EDA were use of an adjusted body weight in the body-surface area (BSA) equation and capping BSA. Factors with the most impact on EDA were curative intent, degree of obesity, type of chemotherapy, and performance status.
  
  
  CONCLUSIONS
  There is no standard of practice regarding EDA of chemotherapy in obese adult patients. Although many factors affect this decision, intent of treatment, degree of obesity, performance status, age, and type of medication seem to carry the most weight.
authors.affiliation: University of Colorado Denver School of Pharmacy, Aurora, CO; University of Kentucky HealthCare; and Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Thompson
authors.forename: Amber P
authors.initials: AP
authors.lastname: Lawson
authors.forename: Stephanie D
authors.initials: SD
authors.lastname: Sutphin
authors.forename: Douglas
authors.initials: D
authors.lastname: Steinke
authors.forename: Val R
authors.initials: VR
authors.lastname: Adams
references.citation: Am J Hosp Pharm. 1980 Apr;37(4):519-22
references.pmid: 7377215
references.citation: J Oncol Pract. 2008 May;4(3):108-13
references.pmid: 20856612
references.citation: Cancer. 2008 May 15;112(10):2159-65
references.pmid: 18338813
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4707-13
references.pmid: 17947717
references.citation: J Natl Cancer Inst. 2006 Nov 15;98(22):1647-54
references.pmid: 17105987
references.citation: JAMA. 2006 Apr 5;295(13):1549-55
references.pmid: 16595758
references.citation: Gynecol Oncol. 2008 Jun;109(3):353-8
references.pmid: 18407341
references.citation: Oncogene. 2004 Aug 23;23(38):6365-78
references.pmid: 15322511
references.citation: Nephron. 1976;16(1):31-41
references.pmid: 1244564
references.citation: J Pharm Sci. 1999 Jan;88(1):1-7
references.pmid: 9874695
references.citation: Lancet. 2005 Sep 24-30;366(9491):1108-10
references.pmid: 16182899
references.citation: N Engl J Med. 2003 Apr 24;348(17):1625-38
references.pmid: 12711737
references.citation: Clin Pharmacokinet. 2000 Sep;39(3):215-31
references.pmid: 11020136
references.citation: Cancer. 2003 Aug 1;98(3):484-95
references.pmid: 12879464
references.citation: Clin Pharm. 1985 Jan-Feb;4(1):70-2
references.pmid: 3971686
references.citation: Eur J Cancer. 2007 Feb;43(3):544-8
references.pmid: 17169553
references.citation: Am J Med. 1988 Jun;84(6):1053-60
references.pmid: 3376975
references.citation: Clin Pharmacokinet. 2004;43(15):1127-56
references.pmid: 15568891
references.citation: J Clin Oncol. 1989 Nov;7(11):1748-56
references.pmid: 2681557
references.citation: Bone Marrow Transplant. 2003 Jun;31(11):961-6
references.pmid: 12774045
references.citation: Lancet. 1971 May 8;1(7706):975-6
references.pmid: 4102307
references.citation: Ann Oncol. 2008 May;19(5):898-902
references.pmid: 18272913